ClinicalTrials.gg
Active, not recruitingNCT04136002ECLIPSEUpdated May 14, 2026

Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode

An observational study in Colorectal Cancer, sponsored by Guardant Health, Inc.. Active, not recruiting at 271 sites in United States. Open to participants aged 45 Years to 84 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-14.

Sponsored by Guardant Health, Inc. · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
44,467
Ages
45 Years to 84 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 2,342 studies in Colorectal Neoplasms with a site in United States — 415 open to participants now, 629 under way, 30 of them phase 3. Colorectal Neoplasms · United States.

Enrollment
6th of 325
44,467 · median 220
Started
2019
with 114 others
Observational
326 of 2,342
68 open now
Primary completion
2024-03
later than 22 of 627 live
Registered
1,419th of 2,342
by date

Among the 2,342 studies in Colorectal Neoplasms with a site in United States, this one is the 6th largest by enrollment of the 325 observational ones that give a count, is one of 115 that started in 2019, is one of 326 observational ones, reaches primary completion later than 22 of the 627 other live ones, and was the 1,419th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

415 of the 2,342 studies in Colorectal Neoplasms with a site in United States are open now. Recruiting first, the newest first:

410 more — sign in →

All 415 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 45 Years to 84 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,342 studies in Colorectal Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The ECLIPSE (Evaluation of the ctDNA LUNAR test in an Average Patient Screening Episode) study is a prospective, observational multi-site study without randomization. The primary objective of the study is to evaluate the performance characteristics of a blood-based ctDNA LUNAR-2 test to detect colorectal cancer in a screen-relevant, average risk population.

Read the detailed description

The LUNAR-2 test has been developed to detect malignant disease in screen-relevant patients who would otherwise undergo screening for malignant disease using invasive methodologies such as colonoscopy. The intended use of such a test would be to return a result of ctDNA detected/ ctDNA not detected in a patient eligible for average risk screening for colorectal cancer. Those patients who receive a ctDNA detected result should undergo further investigation with colonoscopy.

In order to define the performance characteristics of the test in a relevant population, this study will perform a blood draw prior to the patient undergoing the standard of care colonoscopy (and all associated preparatory medications) and retrospectively compare the performance characteristics of the LUNAR-2 test with the findings of the index colonoscopy.

Outcomes of patients at one and two-years post-procedure will be collected as secondary endpoints to investigate the possibility of incidental, non-colorectal cancer cases and interval cancers that had not reached the clinical threshold for detection at the time of the index colonoscopy.

03

Conditions studied

  • Colorectal Cancer
04

Who can participate

Ages eligible
45 Years to 84 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Single cohort of patients aged between 45 and 84, with no known high risk features, undergoing routine colorectal cancer screening as standard of care.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects aged 45-84 years at time of consent
  2. Intended to undergo screening colonoscopy
  3. Considered by a physician or healthcare provider as being of 'average risk' for CRC
  4. Willing to consent to blood draw pre-bowel preparation administration prior to undergoing colonoscopy within 60 days of the date of the blood draw
  5. Willing to consent to follow-up for two years as per protocol

Exclusion criteria

Exclusion Criteria:

  1. Undergoing colonoscopy for investigation of symptoms
  2. Has undergone colonoscopy within preceding 9 years
  3. Positive FIT/FOBT result within the previous 6 months
  4. Has completed Cologuard or Epi proColon testing within the previous 3 years
  5. History of colorectal cancer
  6. History of any (patients who have undergone surgical removal of skin squamous cell cancer may be enrolled provided the procedure was completed at least 12 months prior to the date of provision of for the study)
  7. Known diagnosis of inflammatory bowel disease
  8. Currently taking any anti-neoplastic or disease-modifying anti-rheumatic drugs (DMARDs)
  9. Positive family history of colorectal cancer, defined as having one or more first- degree relatives (parent, sibling, or child) with CRC at any age
  10. Known hereditary/germline risk of colorectal cancer (for example, Lynch syndrome or Hereditary Non-Polyposis CRC [HNPCC], or Familial Adenomatous Polyposis [FAP])
  11. Any major physical trauma (e.g. disruption of tissue, surgery, organ transplant, blood product transfusion) within the 30 days leading up to the provision of informed consent
  12. Known medical condition which, in the opinion of the investigator, should preclude enrollment into the study
  13. Participation in a clinical research study in which an experimental medication has been administered or may be administered within the 30 days leading up to providing informed consent or may be administered through the time of colonoscopy
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
44,467 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Sensitivity of colorectal cancer detection

    Sensitivity of colorectal cancer detection

    Time frame: 60 days

  2. Specificity of advanced neoplasia detection

    Specificity of advanced neoplasia detection

    Time frame: 60 days

Secondary outcomes

  1. Positive predictive value of colorectal cancer detection

    Positive predictive value of colorectal cancer detection

    Time frame: 60 days

  2. Negative predictive value of colorectal cancer detection

    Negative predictive value of colorectal cancer detection

    Time frame: 60 days

  3. Sensitivity and specificity of advanced adenoma detection

    Sensitivity and specificity of advanced adenoma detection

    Time frame: 60 days

07

Study locations

271 sites
  • Pinnacle Research Group, LLC
    Anniston, Alabama 36207, United States
  • Lakeview Clinical Research
    Guntersville, Alabama 35976, United States
  • Medical Affiliated Research Center
    Huntsville, Alabama 35801, United States
  • Jasper Summit Research LLC
    Jasper, Alabama 35501, United States
  • Hope Research Institute
    Chandler, Arizona 85224, United States
  • Southeast Valley Gastroenterology
    Chandler, Arizona 85224, United States
  • Prime Medical Group, LLC
    Gilbert, Arizona 85296, United States
  • Hope Research Institute
    Glendale, Arizona 85308, United States
  • GI Research Associates, LLC
    Phoenix, Arizona 85037, United States
  • "Forty-Third Medical Associates Absolute Clinical Research"
    Phoenix, Arizona 85051, United States
  • Del Sol Research Management, LLC
    Tucson, Arizona 85715, United States
  • Novak Clinical Research
    Tucson, Arizona 85741, United States
  • Del Sol Research Management, LLC
    Tuscon, Arizona 85715, United States
  • Preferred Research Partners, Inc
    Little Rock, Arkansas 72211, United States
  • Premier Gastroenterology
    Little Rock, Arkansas 72211, United States
  • Arkansas Gastroenterology
    North Little Rock, Arkansas 72117, United States
  • Associated Gastroenterology Medical Group
    Anaheim, California 92801, United States
  • InSite Digestive Health Care
    Arcadia, California 91006, United States
  • Gastroenterology
    Burlingame, California 94010, United States
  • Ventura County Gastroenterology Medical Group
    Camarillo, California 93012, United States
  • Hope Clinical Research
    Canoga Park, California 91303, United States
  • Alliance Research Institute
    Canoga Park, California 91304, United States
  • Gastro SB Clinic
    Chula Vista, California 91910, United States
  • Precision Research Institute
    Chula Vista, California 91910, United States
  • BG Clinical Research and affiliate of The Clinical Trials Network, LLC
    Encinitas, California 92024, United States
  • Diagnamics, Inc
    Encinitas, California 92024, United States
  • Helping Hands Healthcare Group
    Fullerton, California 92831, United States
  • Paragon RX Clinical, Inc.
    Garden Grove, California 92840, United States
  • Digestive Health Research of Southern California
    Huntington Beach, California 92647, United States
  • United Medical Doctors
    Irvine, California 92618, United States
  • Gastro Care Institute
    Lancaster, California 93534, United States
  • LA Gastroenterology Group
    Los Angeles, California 90004, United States
  • University of Southern California
    Los Angeles, California 90033, United States
  • Gastroenterology Associates of Beverly Hills
    Los Angeles, California 90048, United States
  • Knowledge Research Center
    Orange, California 92868, United States
  • InSite Digestive Health Care-San Gabriel
    Oxnard, California 93030, United States
  • Desert Oasis Healthcare Medical Group
    Palm Springs, California 92262, United States
  • Palm Tree Clinical, Inc
    Palm Springs, California 92262, United States
  • InSite Digestive Health Care - Gastroenterology Associates
    Pasadena, California 91105, United States
  • Northern California Research
    Sacramento, California 95821, United States
  • San Diego Gastroenterology Medical Associates
    San Diego, California 92103, United States
  • SDG Clinical Research, Inc.
    San Diego, California 92103, United States
  • Precision Research Institute
    San Diego, California 92114, United States
  • Medical Associates Research Group
    San Diego, California 92123, United States
  • FOMAT Simoni AGI Medical
    Thousand Oaks, California 91360, United States
  • Med Partners, Inc. dba Premiere Medical Center of Burbank, Inc
    Toluca Lake, California 91602, United States
  • Curebase
    Walnut Creek, California 91789, United States
  • Clinical Research of California
    Walnut Creek, California 94598, United States
  • Gastroenterology Associates of Fairfield County
    Bridgeport, Connecticut 06606, United States
  • CMR of Greater New Haven, LLC
    Hamden, Connecticut 06517, United States
  • Yale University
    New Haven, Connecticut 06519, United States
  • Innovative Medical Research of South Florida, Inc.
    Aventura, Florida 33180, United States
  • Reciomed Clinical Research Network, Inc.
    Boynton Beach, Florida 33472, United States
  • Clinical Research of South Florida, an AMR Company
    Coral Gables, Florida 33134, United States
  • Dolphin Medical Research
    Doral, Florida 33172, United States
  • University of Florida College of Medicine
    Gainesville, Florida 32610, United States
  • Palmetto Research, LLC
    Hialeah, Florida 33016, United States
  • The Center for Gastrointestinal Disorders
    Hollywood, Florida 33021, United States
  • Research Centers of America
    Hollywood, Florida 33024, United States
  • Health Awareness, Inc
    Jupiter, Florida 33458, United States
  • Jupiter Medical Center
    Jupiter, Florida 33458, United States
  • Multi-Specialty Research Associates
    Lake City, Florida 32055, United States
  • University Clinical Research-DeLand, LLC dba Accel Research Sites
    Lake Mary, Florida 32746, United States
  • Florida Research Institute
    Lakewood Rch, Florida 34211, United States
  • University Clinical Research-DeLand, LLC dba Accel Research Sites
    Melbourne, Florida 32901, United States
  • Crystal Biomedical Research
    Miami Lakes, Florida 33014, United States
  • Ocala GI Research, LLC
    Ocala, Florida 34471, United States
  • Sarkis Clinical Trials
    Ocala, Florida 34474, United States
  • Gastroenterology of Greater Orlando
    Orange City, Florida 32763, United States
  • Gastroenterology Institute of Orlando
    Orlando, Florida 32807, United States
  • Advanced Gastroenterology Associates, LLC
    Palm Harbor, Florida 34684, United States
  • Precision Clinical Research, LLC
    Sunrise, Florida 33351, United States
  • Guardian Angel Research Center, LLC
    Tampa, Florida 33614, United States
  • Digestive Health Care of Georgia
    Atlanta, Georgia 30309, United States
  • Emory University School of Medicine
    Atlanta, Georgia 30322, United States
  • Metro Atlanta Gastroenterology, LLC.
    Atlanta, Georgia 30342, United States
  • Columbus Regional Research Institute
    Columbus, Georgia 31904, United States
  • Gastroenterology Consultants of Augusta
    Evans, Georgia 30809, United States
  • SKY Clinical Research Network Group
    Lawrenceville, Georgia 30044, United States
  • Infinite Clinical Trials
    Riverdale, Georgia 30274, United States
  • WR-Mount Vernon Clinical Research, LLC
    Sandy Springs, Georgia 30328, United States
  • Rolphe Adult and Pediatric Medicine
    Union City, Georgia 30291, United States
  • Christie Clinic
    Champaign, Illinois 61822, United States
  • University of Chicago Medicine
    Chicago, Illinois 60654, United States
  • Curebase
    Chicago, Illinois 60656, United States
  • Digestive Health Services
    Downers Grove, Illinois 60515, United States
  • Edward Hines Jr. VA Hospital
    Hines, Illinois 60141, United States
  • Gastroenterology & Internal Medicine Specialist, SC, Avicenna Clinical Research
    Lake Barrington, Illinois 60010, United States
  • Suburban Gastroenterology Ltd
    Naperville, Illinois 60540, United States
  • Comprehensive Gastrointestinal Health
    Northbrook, Illinois 60062, United States
  • DM Clinical Research
    Oak Lawn, Illinois 60453, United States
  • Rockford Gastroenterology Associates, Ltd.
    Rockford, Illinois 61107, United States
  • Digestive Research Alliance of Michiana
    South Bend, Indiana 46635, United States
  • University of Iowa Hospitals and Clinics
    Iowa City, Iowa 52242, United States
  • Alliance for Multispecialty Research, LLC
    El Dorado, Kansas 67042, United States
  • West Glen Gastrointestinal Consultants, P.A.
    Shawnee, Kansas 66217, United States
  • Alliance for Multispecialty Research-Wichita West
    Wichita, Kansas 67205, United States
  • Kansas Gastroenterology, LLC
    Wichita, Kansas 67226, United States
  • Tri-State Gastroenterology Associates
    Crestview Hills, Kentucky 41017, United States
  • University of Louisville Research Foundation
    Louisville, Kentucky 40202, United States

Showing the first 100 of 271 sites. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Lo YMD. Cell-free DNA for Colorectal Cancer Screening. N Engl J Med. 2024 Mar 14;390(11):1047-1050. doi: 10.1056/NEJMe2311101. No abstract available. PubMed 38477993 ↗
  • Chung DC, Gray DM 2nd, Singh H, Issaka RB, Raymond VM, Eagle C, Hu S, Chudova DI, Talasaz A, Greenson JK, Sinicrope FA, Gupta S, Grady WM. A Cell-free DNA Blood-Based Test for Colorectal Cancer Screening. N Engl J Med. 2024 Mar 14;390(11):973-983. doi: 10.1056/NEJMoa2304714. PubMed 38477985 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2019 to primary completion in Mar 2024, 53 months.

Of 117 industry-sponsored observational studies under Colorectal Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 60. This study's 53 months is above that.

Counting every sponsor, half of 648 studies reached it within 52 months; a quarter within 27 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2019
First posted
Oct 23, 2019
StartActual
Oct 8, 2019
Primary completionActual
Mar 20, 2024
CompletionEst.
Aug 5, 2027
Last update
May 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04136002
Lead sponsor
Guardant Health, Inc.
Collaborators
Premier Research
Responsible party
Sponsor
First posted
Oct 23, 2019
Start date
Oct 8, 2019
Primary completion
Mar 20, 2024
Completion
Aug 5, 2027 (estimated)
Last update
May 14, 2026

Study contacts

Craig Eagle, MD
principal investigator · Guardant Health, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion